β Amyloid (Aβ) 1-42 Antibody (Rabbit mAb) [M4F1]

Application: Reactivity: Mouse, Human

Usage Information

Dilution
IHC1:2000

Application
IHC

Reactivity
Mouse, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
87 kDa

Datasheet & SDS

Biological Description

Specificity
β Amyloid (Aβ) 1-42 Antibody (Rabbit mAb) [M4F1] detects endogenous levels of total β Amyloid (Aβ) 1-42 protein.

Clone
M4F1

Synonym(s)
A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II

Background
β-Amyloid 1-42 is a peptide fragment released from the amyloid precursor protein through sequential proteolytic cleavage, representing the primary product of the amyloidogenic processing branch of APP metabolism. Full-length APP undergoes cleavage by β-secretase (BACE1) at the cell surface and within endocytic compartments, generating a soluble N-terminal fragment, sAPPβ, and a membrane-retained C-terminal fragment, C99. Sequential cleavage of C99 by the γ-secretase complex, composed of presenilin, nicastrin, Pen-2, and Aph-1 subunits, releases Aβ into the extracellular space along with the intracellular domain AICD, which itself acts as a transcriptional regulator influencing further APP expression. This amyloidogenic route operates in competition with the non-amyloidogenic pathway, where α-secretase cleavage within the Aβ domain precludes intact peptide formation and instead yields the neuroprotective fragment sAPPα, positioning secretase balance as the determinant of Aβ output. Once generated, Aβ1-42 self-associates into soluble oligomers and higher-order fibrils that accumulate as extracellular plaques, interacting with neuronal membrane lipids, ion channels, and surface receptors to disrupt synaptic signaling and calcium homeostasis. Aβ pathology intersects with tau biology through shared kinase signaling intermediates that promote tau hyperphosphorylation, driving microtubule destabilization and neurofibrillary tangle formation as a parallel pathological cascade. BACE1 cleavage constitutes the rate-limiting step of the amyloidogenic pathway, and its activity is influenced by cellular trafficking, membrane lipid raft composition, and stress-responsive kinase signaling, including JNK and p38 MAPK pathways that elevate BACE1 expression under oxidative conditions. Aβ1-42 also accumulates within cerebral blood vessel walls, contributing to cerebral amyloid angiopathy as a distinct but overlapping vascular pathology.

Background

β-Amyloid 1-42 is a peptide fragment released from the amyloid precursor protein through sequential proteolytic cleavage, representing the primary product of the amyloidogenic processing branch of APP metabolism. Full-length APP undergoes cleavage by β-secretase (BACE1) at the cell surface and within endocytic compartments, generating a soluble N-terminal fragment, sAPPβ, and a membrane-retained C-terminal fragment, C99. Sequential cleavage of C99 by the γ-secretase complex, composed of presenilin, nicastrin, Pen-2, and Aph-1 subunits, releases Aβ into the extracellular space along with the intracellular domain AICD, which itself acts as a transcriptional regulator influencing further APP expression. This amyloidogenic route operates in competition with the non-amyloidogenic pathway, where α-secretase cleavage within the Aβ domain precludes intact peptide formation and instead yields the neuroprotective fragment sAPPα, positioning secretase balance as the determinant of Aβ output. Once generated, Aβ1-42 self-associates into soluble oligomers and higher-order fibrils that accumulate as extracellular plaques, interacting with neuronal membrane lipids, ion channels, and surface receptors to disrupt synaptic signaling and calcium homeostasis. Aβ pathology intersects with tau biology through shared kinase signaling intermediates that promote tau hyperphosphorylation, driving microtubule destabilization and neurofibrillary tangle formation as a parallel pathological cascade. BACE1 cleavage constitutes the rate-limiting step of the amyloidogenic pathway, and its activity is influenced by cellular trafficking, membrane lipid raft composition, and stress-responsive kinase signaling, including JNK and p38 MAPK pathways that elevate BACE1 expression under oxidative conditions. Aβ1-42 also accumulates within cerebral blood vessel walls, contributing to cerebral amyloid angiopathy as a distinct but overlapping vascular pathology.

References
https://pubmed.ncbi.nlm.nih.gov/40722590/ https://pubmed.ncbi.nlm.nih.gov/24103387/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%